MedTrace Logo

Proteomics of Severe Traumatic Brain Injury: A Feasibility Study

NCT00522496 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 8

Last updated 2009-02-24

No results posted yet for this study

Summary

The purpose of this study is to:

1. Determine the temporal course of matrix metalloproteinase (MMP) expression in patients wiht severe traumatic brain injury
2. Determine the temporal course of the expression of MMP-related inflammatory mediators of secondary injury in patients with severe traumatic brain injury
3. Describe the association of physiological changes and standard microdialysis analyte measures (lactate, pyruvate, lactate/pyruvate ratio, and glucose) to MMP and neuroinflammatory marker concentrations.

Conditions

  • Brain Injuries, Traumatic

Sponsors & Collaborators

  • Canadian Intensive Care Foundation

    collaborator OTHER

  • University of Calgary

    lead OTHER

Principal Investigators

  • Zygun A David, MD · University of Calgary

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Completion
2009-08-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00522496 on ClinicalTrials.gov